Covis Pharma Holdings (Covis Holdings), a specialist pharmaceuticals firm, has appointed industry veteran Dean Mitchell as Executive Chairman.
Mitchell replaces former Executive Chairman James Lenehan, who will continue as a director of the company.
Prior to joining Covis Holdings, Mitchell held senior positions at Bristol-Myers Squibb from 2001 to 2004, where he was a member of the company's Corporate Executive Committee. He was President of Bristol-Myers Squibb's North America Primary Care and International Pharmaceuticals businesses from 2002 to 2004.
He previously spent 14 years at GlaxoSmithKline in senior management, product strategy and business development positions, where he led the merger of the company's global clinical development and marketing groups.
Most recently, Mitchell was President and CEO of Lux Biosciences, a biotechnology company focused on the treatment of ophthalmic diseases.
He was also previously CEO of animal pharmaceutical company Alpharma, which was acquired by King Pharmaceuticals and CEO of Guilford Pharmaceuticals, a speciality pharmaceutical company that was subsequently acquired by MGI Pharma.
